Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant NSCLC
NCT03994393Phase 2Unknown
- Sponsor
- University of Sydney
- Start
- Oct 2018
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by University of Sydney. Status: unknown.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03994393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994393.